Key Highlights

  • Hemab Therapeutics shares closed up 10% at $43.31 after reporting Phase 2 long-term extension data for sutacimig (HMB-001) in Glanzmann thrombasthenia.
  • Results from 34 patients with up to 15.9 months of drug exposure showed a 92% reduction in treated bleeding events and an 84% reduction in the mean annualized treated bleeding rate in the low-dose cohort.
  • The trial confirmed successful hemostatic control across three surgical procedures and a tolerable safety profile, with Grade 2 thromboembolic events limited to high-exposure or multi-risk-factor groups.
  • Following alignment with the FDA on a 0.2mg/kg weekly dose, Hemab plans to initiate its registration-directed Phase 3 trial during the second half of 2026.

Hemab Therapeutics (NASDAQ: COAG) shares closed up 10% at $43.31 after the company reported favorable clinical outcomes from its Phase 2 long-term extension study of sutacimig (HMB-001), evaluated for the subcutaneous prevention of bleeding events in patients with Glanzmann thrombasthenia (GT), a rare inherited platelet disorder that impairs normal blood clot formation.

The long-term extension data, drawn from 34 patients with up to 15.9 months of drug exposure, showed a 92% reduction in treated bleeding events, a substantial improvement speaking to sutacimig's potential to meaningfully reduce the bleeding burden faced by patients with this rare and difficult-to-manage condition. In the low-dose cohort specifically, the study showed an 84% reduction in the mean annualized treated bleeding rate (ATBR).

Beyond routine bleeding prevention, the trial also confirmed successful hemostatic control across three surgical procedures performed on patients receiving sutacimig. Surgical settings represent a particularly high-risk scenario for patients with bleeding disorders, so demonstrating effective clot formation and bleeding control during these procedures provides important supportive evidence for the drug's clinical utility beyond everyday bleeding prophylaxis.

Safety data showed a tolerable profile overall, with Grade 2 thromboembolic events limited specifically to high-exposure or multi-risk-factor patient groups. This finding suggests the thromboembolic risk associated with sutacimig appears to be concentrated in identifiable higher-risk subgroups rather than occurring broadly across the treated population.

Hemab also disclosed alignment with the FDA on a 0.2mg/kg weekly dose, an important regulatory milestone that provides clarity on the specific dosing regimen expected to move forward into pivotal-stage development, alongside positive preclinical data in Factor VII deficiency, a separate rare bleeding disorder.

Building on this combination of long-term extension efficacy and safety data plus FDA dose alignment, Hemab plans to initiate its registration-directed Phase 3 trial for sutacimig in Glanzmann thrombasthenia during the second half of 2026, representing the next major milestone in the drug's path toward a potential approval for this rare disease population.